Mitophagy is a selective autophagic process responsible for removing damaged mitochondria. In a recent review, Chinese researchers explored the molecular mechanisms that govern mitophagy and its aberrant role in the onset and progression of breast cancer. It offers a detailed overview of the dual functions of mitophagy in breast cancer advancement, investigates the potential of mitophagy-related genes and proteins as biomarkers and therapeutic targets, and emphasizes the significance of mitophagy regulators in enhancing treatment outcomes.

The review by Professor Rui-Hua Xu’s team from Sun Yat-Sen University synthesizes pivotal clinical evidence to address a central challenge: while immunotherapy has revolutionized cancer care, its success varies dramatically across different gastrointestinal cancers. The authors introduce a practical "three-strata" framework that categorizes tumors based on their underlying immunobiology—from highly immunogenic to deeply immunosuppressive—and outlines distinct, optimized therapeutic strategies for each group, offering a clear roadmap for clinicians and researchers.

Canine cancer patients receiving a new form of immunotherapy lived longer or shorter depending on the composition of their microbiome, the community of organisms living in their gut.